Search clinical trials for: Capecitabine/Eribulin/Gemcitabine/Paclitaxel/Nab-paclitaxel

Total 1234 results

Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Completed

Gemcitabine and Carboplatin Followed by Paclitaxel in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

Lung Cancer

United States
National Cancer Institute (NCI)

Unknown

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced and/or Recurrent Head and Neck Cancer

Head and Neck Cancer

United States
AstraZeneca

Active, not recruiting

Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION) (ORION)

Non-small Cell Lung Cancer NSCLC

United Kingdom, Belgium, United States, Korea, Republic of, Hungary, Japan, Russian Federation, Poland, Ukraine, India, Mexico, Netherlands
BeiGene

Recruiting

A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer | Metastatic Non-small Cell Lung Cancer

United States, China, Australia, Spain, France, Malaysia, Italy, Canada, Thailand, Georgia, Brazil, Korea, Republic of, Singapore, Moldova, Republic of, Romania
Bristol-Myers Squibb

Active, not recruiting

A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Metastatic Non-small Cell Lung Cancer

Australia, Russian Federation, United States, Argentina, Austria, Belgium, Brazil, Chile, France, Germany, Italy, Mexico, Poland, Romania, Spain, Switzerland, United Kingdom, Ireland, Netherlands
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of Pembrolizumab (MK-3475) With or Without Maintenance Olaparib in First-line Metastatic Squamous Non-small Cell Lung Cancer (NSCLC, MK-7339-008/KEYLYNK-008)

Carcinoma, Squamous Cell, Non-small-cell Lung

Poland, Korea, Republic of, United States, Argentina, Australia, Austria, Brazil, Canada, France, Germany, Japan, Mexico, New Zealand, Romania, Russian Federation, Spain, Taiwan, Turkey, Ukraine, United Kingdom
Celgene

Completed

ABI-007 In Combination With Bevacizumab in Women With Metastatic Breast Cancer

Metastatic Breast Cancer

United States
NewLink Genetics Corporation

Terminated

Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer (PILLAR)

Pancreatic Cancer | Locally Advanced Malignant Neoplasm | Pancreatic Carcinoma Non-resectable

United States
Shanghai Pulmonary Hospital, Shanghai, China

Not yet recruiting

Neoadjuvant Therapy With Toripalimab and JS004 Combined With Platinum-based Doublet Chemotherapy for Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer: A Randomised Controlled, Open-label, Phase 2 Trial

Stage III Non-small Cell Lung Cancer
Guangdong Provincial People's Hospital
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

Neoadjuvant Immunotherapy in Rare Mutations Localized NSCLC

Non-Small Cell Lung Cancer | BRAF V600 Mutation | MET Amplification | MET Exon 14 Skipping Mutation | RET Driver Mutation | Erb-B2 Receptor Tyrosine Kinase Exon 20 Mutation

China
NYU Langone Health
Celgene Corporation

Terminated

Phase I/II Trial of the Combination of Lenalidomide (Revlimid) and Nab-paclitaxel (Abraxane) in the Treatment of Relapsed/Refractory Multiple Myeloma (rev/abraxane)

Relapsed or Refractory Multiple Myeloma

United States
Southern Italy Cooperative Oncology Group

Completed

Alimta and Gemcitabine in Non-Small Cell Lung Cancer (ANGEL)

Non-Small Cell Lung Cancer | Stage IIIB or IV

Italy
EpicentRx, Inc.

Completed

RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)

Carcinoma, Non-Small-Cell Lung | Ovarian Epithelial Cancer | Neuroendocrine Tumors | Small Cell Carcinoma

United States
Shanghai Pulmonary Hospital, Shanghai, China

Not yet recruiting

Perioperative Immunotherpay Versus Adjuvant Immunotherapy for Resectable Non-small Cell Lung Cancer

Stage II-IIIB(N2) Non-small Cell Lung Cancer

China
Nationwide Children's Hospital

Completed

Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx)

CNS Germ Cell Tumor

United States
Radiation Therapy Oncology Group
National Cancer Institute (NCI)

Completed

Gemcitabine, Carboplatin or Paclitaxel Plus Radiation Therapy in Treating Patients With Stage IIIA or IIIB Non-Small Cell Lung Cancer

Lung Cancer

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0329, Gemcitabine and Paclitaxel in Treating Patients With Persistent, Recurrent, or Metastatic Head and Neck Cancer

Head and Neck Cancer

United States
The Second People's Hospital of Sichuan

Unknown

The Maintenance Therapy of Capecitabine of Advanced Gastric Cancer (GZH-001)

Advanced Gastric Cancer
OHSU Knight Cancer Institute
Oregon Health and Science University

Not yet recruiting

Onvansertib in Combination With Gemcitabine and Nab-paclitaxel for the Treatment of Patients With Locally-advanced, Unresectable, or Metastatic Pancreatic Ductal Adenocarcinoma

Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Ductal Adenocarcinoma | Unresectable Pancreatic Adenocarcinoma

United States
Lund University Hospital
Danish Breast Cancer Cooperative Group; Swedish Breast Cancer Group; Finnish... and other collaborators

Recruiting

NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC

Breast Cancer | Triple Negative Breast Neoplasms

Denmark, Sweden
MedSIR
Hoffmann-La Roche

Completed

Ipatasertib Plus Non-Taxane Chemotherapy for Advanced or Metastatic Triple-Negative Breast Cancer (PATHFINDER)

Triple Negative Breast Cancer

Spain, Portugal
Hoffmann-La Roche

Withdrawn

A Study of RO5083945 in Combination With Cisplatin and Gemcitabine or Carboplatin and Paclitaxel in Patients With Advanced or Recurrent Non-Small Cell Lung Cancer of Squamous Histology Who Have Not Received Prior Chemotherapy for The Metastatic Disease

Non-Squamous Non-Small Cell Lung Cancer
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Combination Chemotherapy and Computer-Planned Radiation Therapy in Treating Patients With Unresectable Stage III Non-Small Cell Lung Cancer

Lung Cancer

United States
Pancreatic Cancer Research Team

Completed

Gemcitabine+Nab-paclitaxel and FOLFIRINOX and Molecular Profiling for Patients With Advanced Pancreatic Cancer

Stage IV Pancreatic Cancer

United States
Henan Cancer Hospital

Recruiting

Comparing the Efficacy of Nab-PH+Pyrrolitinib and TCbHP in the Neoadjuvant Treatment of HER2 Positive BC

Breast Cancer | HER2-positive Breast Cancer

China
Nisha Mohindra, MD
Merck Sharp & Dohme LLC; Hoosier Cancer Research Network; Celgene Corporation

Terminated

Carboplatin/Nab-Paclitaxel and Pembrolizumab in NSCLC

Non-Small Cell Lung Cancer

United States
Massachusetts General Hospital
Dana-Farber Cancer Institute; Genentech, Inc.; Celgene Corporation

Completed

Carboplatin, Abraxane, and Bevacizumab in Previously Untreated Patients With Advanced Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer

United States
Eli Lilly and Company

Completed

Gemcitabine Combinations in Metastatic Breast Cancer (MBC), 1st Line

Breast Cancer

China, India, Turkey, Korea, Republic of, Brazil, Mexico
Genelux Corporation
GOG Foundation

Recruiting

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

Fallopian Tube Cancer | Platinum-resistant Ovarian Cancer | Platinum-refractory Ovarian Cancer | Primary Peritoneal Cancer | High-grade Serous Ovarian Cancer | Endometrioid Ovarian Cancer | Ovarian Clear Cell Carcinoma

United States
Sichuan Cancer Hospital and Research Institute

Recruiting

Toripalimab Combined With Bevacizumab, Nab-paclitaxel and Carboplatin for Untreated Metastatic Pulmonary Sarcomatoid Carcinoma

Lung Diseases | Thoracic Neoplasms | Non-small Cell Lung Cancer | Pulmonary Sarcomatoid Carcinoma

China
Seoul National University Hospital

Active, not recruiting

Pembrolizumab Plus Chemotherapy in 1st Line Treatment of Pancreatic Cancer

Pancreatic Cancer | Chemotherapy Effect

Korea, Republic of
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Gemcitabine Hydrochloride, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Metformin Hydrochloride, and a Standardized Dietary Supplement in Treating Patients With Pancreatic Cancer That Cannot be Removed by Surgery

Pancreatic Adenocarcinoma | Unresectable Pancreatic Carcinoma | Stage III Pancreatic Cancer AJCC v6 and v7 | Stage IV Pancreatic Cancer AJCC v6 and v7

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Gemcitabine, and Bevacizumab in Treating Patients With Metastatic Breast Cancer

Breast Cancer

United States
Suzhou Transcenta Therapeutics Co., Ltd.
Bristol-Myers Squibb

Recruiting

A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors

Advanced Cancer

China
Gilead Sciences
Arcus Biosciences, Inc.

Recruiting

Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer (STAR-121)

Non-small Cell Lung Cancer

Taiwan, Hong Kong, United States, Netherlands, United Kingdom, Italy, Korea, Republic of, Spain, Israel, Japan, France, Portugal, China, Turkey, Brazil, Mexico, Austria, Germany, Belgium, Chile, Argentina, Singapore, Canada
Celgene

Completed

Phase III Study of ABI-007(Albumin-bound Paclitaxel) Plus Gemcitabine Versus Gemcitabine in Metastatic Adenocarcinoma of the Pancreas

Metastatic Pancreatic Cancer

United States, Canada, Spain, Italy, Australia, Germany, France, Austria, Belgium, Russian Federation, Ukraine
Celgene

Completed

Gemcitabine Plus Albumin-bound Paclitaxel In Patients With Advanced Metastatic Pancreatic Cancer

Metastatic Pancreatic Cancer

United States
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Active, not recruiting

Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread

Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Adenocarcinoma

United States
ETOP IBCSG Partners Foundation

Completed

MEtronomic TrEatment Option in Advanced bReast cAncer (METEORA-II)

Breast Cancer

Italy
Peking University
Qilu Pharmaceutical Co., Ltd.

Recruiting

Nab-paclitaxel Combined With Bevacizumab in the Treatment of Metastatic Neuroendocrine Carcinoma

Neuroendocrine Carcinoma

China
Jazz Pharmaceuticals

Not yet recruiting

A Phase 3, Randomized, Open-label, Controlled Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer

Metastatic HER2-positive Breast Cancer
Fudan University
Merck Sharp & Dohme LLC

Recruiting

Induction of Cisplatin/Nab-paclitaxel/Pembrolizumab Followed by Olaparib/Pembrolizumab Maintenance in mTNBC Patients

Triple Negative Breast Cancer

China
UNICANCER
National Cancer Institute, France

Recruiting

PD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung Cancer (NIRVANA-LUNG)

Non Small Cell Lung Cancer | Non Small Cell Lung Cancer Metastatic | Non-Small Cell Carcinoma of Lung, TNM Stage 4

France, Monaco
Novartis Pharmaceuticals

Withdrawn

Study of Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Platinum-based Doublet Chemotherapy as First-line Treatment for Participants With Locally Advanced or Metastatic NSCLC. (AdvanTIG-306)

Non-small Cell Lung Cancer (NSCLC)
Jenny C. Chang, MD
The Methodist Hospital Research Institute

Completed

T-DM1 With Abraxane and Lapatinib for Metastatic HER2 Positive Breast Cancer (STELA)

Metastatic Breast Cancer

United States
Fudan University

Unknown

Second-Line Adjuvant Therapy With Nab-Paclitaxel Plus Gemcitabine Versus Oxaliplatin Plus Folinic Acid and Fluorouracil for Gemcitabine-Refractory Pancreatic Cancer After Curative Resection

Stage ⅠA Pancreatic Cancer | Stage ⅠB Pancreatic Cancer | Stage ⅡA Pancreatic Cancer | Stage ⅡB Pancreatic Cancer

China
Radiation Therapy Oncology Group
National Cancer Institute (NCI)

Completed

Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage II or Stage III Bladder Cancer

Bladder Cancer

United States, Canada
Hoffmann-La Roche

Completed

A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer

Ovarian Cancer

Belgium, Spain, Canada, Russian Federation, United Kingdom, Hungary, Italy, Poland, Netherlands
Sanofi

Completed

Gemcitabine/Oxaliplatin (GEMOX) vs Carboplatin/Paclitaxel (CP) in Non-Small Cell Lung Cancer (NSCLC)

Carcinoma, Non-Small-Cell Lung

United States
Abramson Cancer Center at Penn Medicine

Completed

A Randomized Pilot/Pharmacodynamic/Genomic Study of Neoadjuvant Paricalcitol to Target the Microenvironment in Resectable Pancreatic Cancer

Adenocarcinoma of the Pancreas

United States

Search clinical trials for: Capecitabine/Eribulin/Gemcitabine/Paclitaxel/Nab-paclitaxel

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kazakhstan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations